Previous 10 | Next 10 |
BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-relat...
BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-relat...
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with clinically meaningful reductions of 24-30% achieved with a single PAXTRAVA implant Generally well tolerated with no impact on cornea...
2024-04-01 10:09:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Three under-$15 stocks stand out in the stock market for their massive potential and strategic positioning across diverse sectors. They have all carved unique paths towards growth. Each present...
BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative...
2024-03-26 07:07:27 ET More on Ocular Therapeutix Ocular Therapeutics' Impressive Surge: A Strategic Insight Ocular Therapeutix GAAP EPS of -$0.35 misses by $0.05, revenue of $14.8M misses by $0.91M Read the full article on Seeking Alpha For further details s...
2024-03-25 17:15:09 ET Gainers: Stoke Therapeutics ( STOK ) +87% . AnaptysBio ( ANAB ) +8% . Amneal Pharmaceuticals ( AMRX ) +6% . Omega Therapeutics ( OMGA ) +5% . MoneyHero ( MNY ) +5% . Losers: Ocular Therapeutix...
2024-03-19 16:04:27 ET Summary Ocular Therapeutics' stock has surged 184% in six months, driven by promising clinical assets in eye disease treatments. Dextenza's success illustrates Ocular's Elutyx technology potential, but Paxtrava faces tough competition and logistical challeng...
2024-03-13 09:30:04 ET Piper Sandler analyst issues MARKET PERFORM recommendation for OCUL on March 13, 2024 08:01AM ET. The previous analyst recommendation was Market Perform. OCUL was trading at $9.29 at issue of the analyst recommendation. The overall analyst consensu...
2024-03-12 14:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for OCUL on March 12, 2024 12:42PM ET. The previous analyst recommendation was Market Outperform. OCUL was trading at $9.145 at issue of the analyst recommendation. The overall analyst ...
News, Short Squeeze, Breakout and More Instantly...
Ocular Therapeutix Inc. Company Name:
OCUL Stock Symbol:
NASDAQ Market:
Ocular Therapeutix Inc. Website:
BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company ...
BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative t...
First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; q...